{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1259159429", "close" : "1259182829", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
ap

Alkermes says opioid blocker met goal in studies

Alkermes says potential drug for addiction or nervous system ailments met goal in early trials

  • On 10:42 am EDT, Tuesday October 13, 2009

CAMBRIDGE, Mass. (AP) -- Alkermes Inc. said Tuesday that a drug for addiction and nervous system disorders met its goal in two early stage clinical trials.

The company said it plans to start a midstage study of the drug before the end of this year. The product is designated ALKS 33 and is intended to block opioid receptors, and Alkermes said those receptors are involved in gastrointestinal and immune disorders, pain, addiction, and psychiatric illness.

In morning trading, Alkermes shares rose 1 cent to $8.60.

Related Headlines

Related Blog Headlines

Top Stories

Related Message Boards

Sponsored Links

Copyright © 2009 The Associated Press. All rights reserved. The information contained in the AP News report may not be published, broadcast, rewritten, or redistributed without the prior written authority of The Associated Press.